- Home
- DTIL
as 12-18-2024 10:35am EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 44.1M | IPO Year: | 2019 |
| Target Price: | $39.50 | AVG Volume (30 days): | 104.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.56 - $19.43 | Next Earning Date: | 11-04-2024 |
| Revenue: | $75,096,000 | Revenue Growth: | 43.62% |
| Revenue Growth (this year): | 50.33% | Revenue Growth (next year): | -72.12% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kelly John Alexander | DTIL | Chief Financial Officer | Nov 21 '24 | Buy | $6.76 | 3,000 | $20,280.00 | 38,073 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Nov 2 '24 | Sell | $8.19 | 588 | $4,815.72 | 7,969 | |
| Amoroso Michael | DTIL | President and CEO | Nov 2 '24 | Sell | $8.19 | 3,012 | $24,668.28 | 28,537 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Precision BioSciences to Participate in Upcoming November Investor Conferences
Business Wire
a month ago
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Zacks
a month ago
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
Associated Press Finance
a month ago
Precision BioSciences: Q3 Earnings Snapshot
Business Wire
a month ago
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Zacks
2 months ago
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
Business Wire
2 months ago
Precision BioSciences to Report Third Quarter Results on November 4, 2024
Business Wire
2 months ago
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.